课题基金 / 基金详情

Determinants of TB control, relapse and reinfection

Determinants of TB control, relapse and reinfection
结核病控制、复发和再感染的决定因素
批准号:
10621299
负责人:
SABINE EHRT
金额:
$256.5万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
未结题
起止时间:
2021-07-01 至 2026-04-30

项目摘要

项目成果

SABINE EHRT的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB), continues to be a severe global health problem. TB is multifaceted, but a central clinical and microbiologic feature of the disease is the ability of Mtb to resist complete elimination, both by the host immune system and by chemotherapeutic agents with potent growth inhibitory activity. This persistence in the face of immunologic and antibiotic pressure underlies several important facets of TB disease, including 1) the existence of latent tuberculosis infection (LTBI) and, in the setting of immunologic failure of LTBI control, its role in the genesis of active TB and 2) the prolonged course of TB antibiotic therapy, which requires 6 months of multidrug therapy to achieve reliable clinical cure. Rather than producing complete bacterial eradication in all treated subjects, cure following TB chemotherapy is now understood to be an antibiotic induced paucibacillary state in which prevention of relapse depends in part on poorly understood host factors. The host and bacterial determinants that mediate these two interrelated types of persistence are only partially understood, a knowledge gap the Tri-I-TBRU aims to fill. We propose a set of 3 intersecting projects and 3 cores all focused on different facets of the problem of paucibacillary TB, both post treatment and LTBI. The projects will use samples and clinical data from TB cohorts at our clinical site at GHESKIO in Port Au Prince Haiti, to examine the immunologic, microbiomic, transcriptomic, pharmacokinetic, and genetic factors that influence or predict the transition points between paucibacillary states of TB disease and active transmissible infection. These human studies will be compared and contrasted with a new mouse model of paucibacillary infection that will allow us to test mechanistic hypotheses about the host and bacterial determinants of paucibacillary disease. This work with be conducted by a team of highly collaborative investigators who have who have worked well together for several years.
期刊论文(7)
专著(0)
科研奖励(0)
会议论文
Inborn errors of human transcription factors governing IFN-γ antimycobacterial immunity.
控制 IFN-γ 抗分枝杆菌免疫的人类转录因子的先天性错误。
DOI: 10.1016/j.coi.2023.102296
发表时间: 2023
期刊: Current opinion in immunology
影响因子: 7
作者: [Ogishi,Masato, Yang,Rui, Rosain,Jérémie, Bustamante,Jacinta, Casanova,Jean-Laurent, Boisson-Dupuis,Stéphanie]
通讯作者: Boisson-Dupuis,Stéphanie
DOI: 10.1073/pnas.2314225120
发表时间: 2023-11-14
期刊: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
影响因子: 11.1
作者: [Zhang, Peng, Chaldebas, Matthieu, Ogishi, Masato, Al Qureshah, Fahd, Ponsin, Khoren, Feng, Yi, Rinchai, Darawan, Milisavljevic, Baptiste, Han, Ji Eun, Moncada-Velez, Marcela, Keles, Sevgi, Schroeder, Bernd, Stenson, Peter D., Cooper, David N., Cobat, Aurelie, Boisson, Bertrand, Zhang, Qian, Boisson-Dupuis, Stephanie, Abel, Laurent, Casanova, Jean- Laurent]
通讯作者: Casanova, Jean- Laurent
DOI: 10.1084/jem.20220484
发表时间: 2023-01-02
期刊: The Journal of experimental medicine
影响因子: --
作者: []
通讯作者:
Mycobacterium tuberculosis resisters despite HIV exhibit activated T cells and macrophages in their pulmonary alveoli.
尽管存在艾滋病毒,但结核分枝杆菌仍具有抵抗力,其肺泡中的 T 细胞和巨噬细胞被激活。
DOI: 10.21203/rs.3.rs-3889020/v1
发表时间: 2024
期刊: Research square
影响因子: --
作者: [Schurr,Erwin, Dallmann-Sauer,Monica, Fava,Vinicius, Malherbe,Stephanus, McDonald,Candice, Orlova,Marianna, Kroon,Elouise, Cobat,Aurélie, Boisson-Dupuis,Stéphanie, Hoal,Eileen, Abel,Laurent, Möller,Marlo, Casanova,Jean-Laurent, Walzl,Gerhard, ]
通讯作者:
M. tuberculosis carbon metabolism during infection
Tri-Institutional TRAC Basic Science Core
Tri-Institutional TRAC Basic Science Core
Turning Mycobacterium tuberculosis appetite for fatty acids against itself
海外基金